BTIG analyst Yun Zhong reiterated a Buy rating on Amicus (NASDAQ:FOLD) Therapeutics on Wednesday, setting a price target of $15, which is approximately 47.20% above the present share price of $10.19.
Zhong expects Amicus Therapeutics to post earnings per share (EPS) of -$0.19 for the fourth quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Amicus, with an average price target of $14.25.
The analysts price targets range from a high of $16 to a low of $12.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $77.41 million and a net profit of -$37.81 million. The company's market cap is $2.72 billion.
According to TipRanks.com, BTIG analyst Yun Zhong is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.2% and a 35.29% success rate.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.